Chronic Heart Failure - COngestion eValuation

Chronic Heart Failure Clinical Trial

— CHF-COV  

Official title:

Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05089149
• Other study ID #: 2020PI145-1
• Secondary ID: 2020-A02438-31
• Status: Recruiting
• Phase: N/A
• Start date: December 14, 2021
• Est. completion date: June 14, 2029

Study information

• Verified date: March 2023
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.

The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: June 14, 2029
• Est. primary completion date: December 14, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation

• Age =18 years

• Patients having received complete information regarding the study design and having signed their informed consent form.

• Patient affiliated to or beneficiary of a social security scheme.

Exclusion Criteria:

• Comorbidity for which the life expectancy is = 3 months

• Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion.

• History of lobectomy or pneumonectomy lung surgery

• Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.

• Pregnant woman, parturient or nursing mother

• Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)

• Adult person who is unable to give consent

• Person deprived of liberty by a judicial or administrative decision,

• Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.

Related Conditions & MeSH terms

• Chronic Heart Failure
• Heart Failure

Intervention

Procedure:
• Clinical examination centered on congestion
Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation
• Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography
Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation/ peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional
• Blood sample retrieved for biological assessment and biobanking
Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation

Other:
• Telephone follow-up
Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)

Behavioral:
• Kansas City Cardiomyopathy Questionnaire (KCCQ)
Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge

Locations

Country	Name	City	State
France	CHRU de Nancy	Vandœuvre-lès-Nancy
France	CHRU de Nancy	Vandoeuvre Les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Pr. Nicolas GIRERD

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of death from all causes	composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 2)	24 months after day hospitalization or consultation
Primary	Rate of hospitalisation for acute heart failure	composite endpoint : rate of death from all causes or hospitalisation for acute heart failure during 24 months following day hospitalization (with outcome 1)	24 months after day hospitalization or consultation
Secondary	Rate of death from all causes		24 months after day hospitalization or consultation
Secondary	Rate of hospitalisation for acute heart failure		24 months after day hospitalization or consultation
Secondary	Rate of hospitalisation for cardiovascular reason		24 months after day hospitalization or consultation
Secondary	Rate of death from all causes	composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 7)	24 months after day hospitalization or consultation
Secondary	Rate of hospitalisation for acute heart failure	composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 6)	24 months after day hospitalization or consultation
Secondary	Rate of cardiovascular death		24 months after day hospitalization or consultation
Secondary	NYHA (New York Heart Association) class measured		3, 12 and 24 months after day hospitalization or consulation
Secondary	Natriuretic peptides	BNP or Nt-Pro BNP	At inclusion
Secondary	Renal function assessed by glomerular filtration rate		At inclusion
Secondary	Plasma volume	Calculated from haemoglobin and haematocrit value	At inclusion
Secondary	Rate of Bilirubin		At inclusion
Secondary	Rate of ASAT		At inclusion
Secondary	Rate of ALAT		At inclusion
Secondary	Rate of V factor		At inclusion
Secondary	Blood potassium concentration		At inclusion
Secondary	Liver elastography value	Measured with Fibroscan®	At inclusion
Secondary	Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)		At inclusion and 3, 6 and 24 months